Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the company will participate in the following investor conferences in March 2026. 2026 Jefferies Biotech on the Beach Summit, March 9-11 in Miami Adam Steensberg, President and Chief Executive Officer, will host investor meet ...

Core Viewpoint - Zealand Pharma A/S has reported the total number of shares and voting rights as of December 31, 2025, following a share capital increase due to the exercise of employee warrants [1][2]. Group 1: Share Capital and Voting Rights - As of December 31, 2025, Zealand Pharma has a total of 71,515,045 shares, with a nominal value of DKK 1 each, resulting in a share capital of DKK 71,515,045 and an equal number of voting rights [3]. Group 2: Company Overview - Zealand Pharma A/S is a biotechnology company focused on developing medicines for obesity and metabolic health, leveraging over 25 years of peptide R&D expertise and advanced data-driven approaches [4]. - The company has more than ten drug candidates that have entered clinical development, with two products already on the market and three candidates in late-stage development [4]. - Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in Boston, Massachusetts [4].